Engineering antibody-drug conjugates (ADCs) introduces additional design and development considerations beyond those associated with conventional therapeutic mAbs, particularly around conjugation site selection, ADC stability and homogeneity, and target-mediated internalization. For an ADC to deliver its cytotoxic payload effectively, the antibody must retain its target-binding properties, the conjugate must remain sufficiently stable in circulation, and binding to the target antigen must promote efficient internalization and intracellular payload release.
Integrating molecular and genetic insights earlier in ADC development can help researchers better characterize target antigens, optimize antibody sequence and performance, identify potential sequence and conjugation liabilities, and advance more robust and manufacturable candidates. This eBook explores how genetic technologies can support ADC development across the discovery workflow, from target identification and antibody discovery through engineering, lead optimization, and preparation for downstream development.
Download this ebook to learn
- Sequencing technologies for antibody discovery, characterization, and optimization
- Genetic engineering strategies to enhance antibody performance and functionality
- Strategic library design approaches for identifying high-quality antibody candidates
- Molecular characterization techniques to evaluate antibody function, stability, and developability
